One-Year Follow-Up Of New Iris-Claw Multifocal Phakic Intraocular Lenses For The Correction Of Presbyopia

To evaluate the clinical outcomes and performance of new Iris-claw multifocal phakic intraocular lenses (IOL) for the correction of refractive error and presbyopia simultaneously.

Bright Eye Clinic, Ophthalmology Department, Seoul, South Korea

Korea University College of Medicine, Ophthalmology Department, Seoul, South Koream

Iris claw multifocal phakic IOLs(Artiplus,Ophtec) were implanted in149 eyes of seventy-five patients. Patients were followed up during 12 months ; uncorrected distance visual acuity (UDVA), uncorrected intermediate and near visual acuity (UIVA and UNVA), intraocular pressure, depth of anterior chamber, corneal endothelial cell count and patient satisfaction were assessed. Patient-reported outcomes were also obtained for assessing spectacle independence, satisfaction, bothersome to dysphotopsia, difficulties in daily life tasks.

At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) of UDVA was 0.02 ± 0.05 in operated eyes. UIVA was 0.04 ± 0.07 in both eyes. UNVA was 0.13 ± 0.13 in both eyes. 72 patients (96%) were satisfied with distance, intermediate and near vision, and 3 patients (4%) complained of blurred vision. Spectacle independence for near vision was achieved in 73 patients (97%), and for far vision was achieved in 75 patients (100%). Mean central endothelial cell density was 2654 ± 430 cells/mm(2) preoperatively. After surgery mean endothelial cell density decreased statistically not significant with a loss of 5.2 % to 2517 ± 465 cells/mm(2) (p > 0.05) at last follow-up visit.

Iris-claw multifocal phakic IOL provided good visual outcomes for all distances with a low endothelial cell loss. Additionally, excellent patient satisfaction was achieved with a high level of spectacle independence and acceptable photic phenomena.